Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 157

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 18
Chunk 157
---
 Audit and review of financial statements consist of fees billed for assurance and related services that generally only the statutory auditor could reasonably provide to a client.          
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
2.   Included in the balance are amounts related to additional regulatory filings during the 2025 financial year. All services provided are considered audit services for the purpose of SEC classification.
   PricewaterhouseCoopers was appointed as the Group’s principal independent registered public accounting firm on November 30, 2006. Australian law does not require the Group’s Auditors to be appointed at the Group’s annual general meeting of shareholders. There is an annual engagement letter which is signed, subject to the Group’s audit committee approval, with PricewaterhouseCoopers for audit and review work. No non-audit services were provided by PricewaterhouseCoopers during the 2025, 2024 and 2023 financial years.

F-35

ALTERITY THERAPEUTICS LIMITED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – in Australian dollars (unless otherwise noted)

21. RELATED PARTY TRANSACTIONS
   
a.   Equity Interests in Subsidiaries
-------------------------------------
   Alterity Therapeutics Limited owns 100% of its subsidiaries, Alterity Therapeutics Inc. and Alterity Therapeutics UK Ltd.   
b.   Key Management Personnel Remuneration
------------------------------------------
   The Directors of Alterity during the year:   Mr. Geoffrey Kempler, Chairman Mr. Brian Meltzer, Independent Non-Executive Director Mr. Peter Marks, Independent Non-Executive Director Mr. Lawrence Gozlan, Non-Executive Director   The Key Management Personnel of the Group during the year:   
Dr. David Stamler   Chief Executive Officer
-------------------------------------------
   Remuneration of all key management personnel of the Group is determined by the Board of Directors following recommendation by the Remuneration Committee.   The Group is committed to remunerating senior executives in a manner that is market competitive and consistent with ‘best practice’ including the interests of shareholders. Remuneration packages are based on fixed and variable components, determined by the executive’s position, experience and performance, and may be satisfied via cash or equity.   Please refer to Note 19 for Key Management Personnel Remuneration detail.

F-36

ALTERITY THERAPEUTICS LIMITED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – in Australian dollars (unless otherwise noted)

22. SEGMENT INFORMATION
   The Group’s Chief Executive Officer (Chief Operating Decision Maker